RAIN — Rain Oncology Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Rain Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Rain Therapeutics Reports First Quarter 2022 Financial Results
Rain Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Rain Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Rain Therapeutics Reports Qtrly Loss Per Share Of $0.68
Brief: Rain Therapeutics And Roche To Collaborate On Clinical Trial Of Milademetan Combination With Anti-Pd-L1 Immunotherapy For Various Solid Tumor Indications
Brief: Rain Therapeutics Doses First Patient In Phase 2 Basket Trial Of Milademetan For MDM2-Amplified Advanced Solid Tumors
Rain Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Rain Therapeutics Reports Qtrly Loss Per Share $0.70
Brief: Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial Of Milademetan
Rain Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rain Therapeutics Reports Q2 Results
Brief: Rain Therapeutics Initiates Phase 3 Mantra Clinical Trial Of Milademetan For De-Differentiated Liposarcoma And Provides Patient Update From Prior Clinical Program
Brief: Rain Therapeutics Announces Collaboration With Tempus For Genomic Analysis In Planned Mdm2-Amplified Phase 2 Basket Trial Of Rain-32
Brief: Rain Therapeutics Announces Patient Referral Partnership For The Planned Mdm2-Amplified Phase 2 Basket Trial Of Rain-32
Rain Therapeutics: Surges on advancing cancer treatment to late-stage trial
Brief: Rain Therapeutics Reports First Quarter 2021 Financial Results And Highlights Recent Progress
Brief: Bvf Partners LP Says Rain Therapeutics Securities Were "Undervalued"
Brief: Rain Therapeutics Inc Shares Open 30% Above IPO Price In Nasdaq Debut